Skip to main content
. 2022 Nov 9;22:825. doi: 10.1186/s12879-022-07827-z

Table 1.

Characteristics and outcomes of the HIV-negative CM patients with and without acute/subacute cerebral infarctions (ASCI)

Variable With infarct (n = 14) Without infarct (n = 39) P value
Age [years, median (range)] 49 (42, 69) 61 (41, 67) 0.610
Male:Female 8:6 28:11 0.317
Clinical features [n (%)]
 Fever 8 (57.1%) 24 (61.5%) 0.773
 Headache 10 (71.4%) 31 (79.5%) 0.538
 Vomiting 7 (50.0%) 14 (35.9%) 0.358
 Consciousness disturbance 9 (64.3%) 7 (17.9%) 0.002
 GCS score 14 (6, 15) 15 (15, 15) 0.015
 Cerebral hernia 2 (14.3%) 0
 Cranial nerve deficits 2 (14.3%) 4 (28.6%) 0.684
 Seizures 1 (7.1%) 2 (5.1%) 0.781
 Neck resistance 11 (78.6%) 20 (51.3%) 0.086
Duration of symptoms [n (%)]
 < 1 month 11 (78.6%) 28 (71.8%) 0.559
 1–3 months 2 (14.3%) 6 (15.4%)
 > 3 months 1 (7.1%) 5 (12.8)
ASCI diagnostic time [days, median (range)] 11 (5, 23)
CSF data [median (range)]
 Pressure (mmH2O) 219 (118.75, 300) 260 (170, 300) 0.439
 WBC (cells/μL) 106 (44.25, 245.50) 101 (28, 184) 0.628
 TP (g/L) 1.48 (0.99, 1.80) 1.07 (0.74, 1.78) 0.193
 GLU (mmol/L) 1.63 (0.93, 2.55) 1.97 (1.10, 2.42) 0.716
 CL (mmol/L) 113 (106.95, 117.40) 112.4 (109.0,119.2) 0.724
Treatment
 Treatment time [days, median (range)] 15.5 (5.5, 45.3) 14.0 (5, 23) 0.343
 Liposome Amphotericin B [n (%)] 10 (71.4%) 27 (69.2%) 0.878
 Fluconazole [n (%)] 8 (57.1%) 23 (59%) 0.905
 5-Fluorocytosine [n (%)] 6 (42.9%) 17 (43.6%) 0.827
 Voriconazole [n (%)] 1 (7.1%) 3 (7.7%) 0.947
MRI finding [n (%)]
 Meningeal inflammation 10 (71.4%) 27 (69.2%) 0.878
 Hydrocephalus 7 (50%) 8 (20.5%) 0.036
 Posterior fossa exudates 10 (71.4%) 14 (35.9%) 0.030
 Cryptococcoma 0 1 (2.6%)
Poor outcome [n (%)] 9 (64.3%) 5 (12.8%) 0.001

CSF cerebrospinal fluid, MRI magnetic resonance imaging, N case number, GCS Glasgow Coma Scale, CM Cryptococcal meningitis, WBC white blood cell, TP total protein, GLU glucose, CL chloride